A microRNA (miRNA)-based liquid biopsy known as the Destinex assay demonstrated high accuracy sensitivity in identifying gastric cancer (GC), including early-stage cases, according to research published in JAMA Surgery . Silei Sui, M.D., Ph.D., from the Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center, Monrovia, California, and team sought to address a significant unmet clinical need for cost-effective, minimally invasive approaches to early GC detection in low-GC prevalence countries.

GC remains the third leading cause of cancer-related deaths worldwide, largely due to late-stage diagnosis. Most patients diagnosed at an advanced stage face a poor prognosis and are ineligible for curative treatm

See Full Page